Literature DB >> 17171192

Intranasal insulin administration: a method for dissociating central and peripheral effects of insulin.

Mark A Reger1, Suzanne Craft.   

Abstract

Animal studies have demonstrated the effects of insulin on central nervous system (CNS) functions such as cognition and control of adiposity, but human studies of insulin's CNS effects are more difficult to interpret. Peripheral insulin administration, which increases CNS insulin levels, is associated with increased insulin-stimulated glucose disposal and the release of counter-regulatory hormones--events that can confound CNS results. However, intranasal insulin administration results in direct insulin transport from the nasal cavity to the CNS via intraneuronal and extraneuronal pathways. Recent studies from independent groups of investigators have demonstrated functional, cognitive and adiposity changes following acute and chronic intranasal administration in humans. Available evidence suggests that intranasal insulin administration is safe in humans. Thus, this approach may provide the opportunity to dissociate the central and peripheral effects of insulin. Furthermore, intranasal insulin administration may offer a novel treatment strategy for disorders associated with central insulin abnormalities, such as diabetes and neurodegenerative diseases. (c) 2006 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17171192     DOI: 10.1358/dot.2006.42.11.1007675

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  21 in total

1.  Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures.

Authors:  Neil J Johnson; Leah R Hanson; William H Frey
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

Review 2.  Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Authors:  Peter Riederer; Jasmin Bartl; Gerd Laux; Edna Grünblatt
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

3.  Memory advancement by intranasal insulin in type 2 diabetes (MemAID) randomized controlled clinical trial: Design, methods and rationale.

Authors:  B Galindo-Mendez; J A Trevino; R McGlinchey; C Fortier; V Lioutas; P Novak; C S Mantzoros; L Ngo; V Novak
Journal:  Contemp Clin Trials       Date:  2020-01-07       Impact factor: 2.226

Review 4.  Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease.

Authors:  Therese S Salameh; Elizabeth M Rhea; William A Banks; Angela J Hanson
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-28

Review 5.  Diabetes and Alzheimer's Disease: A Link not as Simple as it Seems.

Authors:  Isabel H Salas; Bart De Strooper
Journal:  Neurochem Res       Date:  2018-12-06       Impact factor: 3.996

Review 6.  Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.

Authors:  Konstantinos Ioannis Avgerinos; Grigorios Kalaitzidis; Antonia Malli; Dimitrios Kalaitzoglou; Pavlos Gr Myserlis; Vasileios-Arsenios Lioutas
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

Review 7.  Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art.

Authors:  Suzanne M de la Monte
Journal:  Expert Opin Drug Deliv       Date:  2013-11-12       Impact factor: 6.648

8.  Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain.

Authors:  Cory C Toth; Nicole M Jedrzejewski; Connie L Ellis; William H Frey
Journal:  Mol Pain       Date:  2010-03-17       Impact factor: 3.395

9.  Intranasal insulin ameliorates experimental diabetic neuropathy.

Authors:  George Francis; Jose Martinez; Wei Liu; Thuhien Nguyen; Amit Ayer; Jared Fine; Douglas Zochodne; Leah R Hanson; William H Frey; Cory Toth
Journal:  Diabetes       Date:  2009-01-09       Impact factor: 9.461

10.  Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment.

Authors:  Suzanne M de la Monte; Ming Tong; Margot Lawton; Lisa Longato
Journal:  Mol Neurodegener       Date:  2009-12-24       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.